PCV68 POTENTIAL COST-EFFECTIVENESS OF A BIOMARKER TEST TO RECLASSIFY PATIENTS WITH AN INTERMEDIATE RISK BASED ON THE FRAMINGHAM RISK SCORE INTO A LOWER OR HIGHER CATEGORY TO OPTIMIZE STATIN THERAPY
Nov 1, 2010, 00:00 AM
10.1016/S1098-3015(11)72411-1
https://www.valueinhealthjournal.com/article/S1098-3015(11)72411-1/fulltext
Section Title :
RESEARCH POSTER ABSTRACTS
Section Order :
567
First Page :
A353
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)72411-1&doi=10.1016/S1098-3015(11)72411-1